MedTrace Logo

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

NCT04880746 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2021-05-11

No results posted yet for this study

Summary

This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

BEAC

Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d

DRUG

Cladribine combined with BEAC

Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    collaborator OTHER

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Harbin Hematology and Oncology Institute

    collaborator OTHER

  • Affiliated Zhongshan Hospital of Dalian University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Weili Zhao · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2024-10-17
Completion
2025-10-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04880746 on ClinicalTrials.gov